Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
Portfolio Pulse from Vandana Singh
Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd (TEVA) have announced a collaboration to co-develop and co-commercialize asset TEV ‘574, a drug currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Under the agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. Both companies will share development costs and net profits and losses. Initial program results are expected in 2024, with Phase 3 trials beginning in 2025.
October 04, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's collaboration with Teva to co-develop and co-commercialize TEV ‘574 could potentially open up a new revenue stream for the company. However, the results of the program are not expected until 2024, and the drug's commercial launch is not expected until around 2028.
The collaboration with Teva could potentially bring in significant revenue for Sanofi, especially considering the estimated $30 billion IBD market. However, the long timeline until the drug's commercial launch introduces uncertainty.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Teva's collaboration with Sanofi to co-develop and co-commercialize TEV ‘574 could potentially bring in significant revenue for the company, with an upfront payment of $500 million and up to $1 billion in development and launch milestones. However, the results of the program are not expected until 2024, and the drug's commercial launch is not expected until around 2028.
The collaboration with Sanofi could potentially bring in significant revenue for Teva, especially considering the upfront payment and development and launch milestones. However, the long timeline until the drug's commercial launch introduces uncertainty.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80